08.27.15
New York, N.Y.-based Manhattan Scientifics Inc. has initiated a share repurchase program. The company’s board of directors designated a program to repurchase, from time to time, at management's discretion, shares of the Manhattan Scientific’s common stock with a value of up to $500,000 in the open market at prevailing market prices over the next 12 months.
“As part of our company’s long-term strategy to further develop its disruptive technologies, we have evaluated the recent price levels and we believe that our common stock represents an attractive investment opportunity for our company,” said Emmanuel Tsoupanarias, president and CEO of Manhattan Scientifics. “We believe that our company is fundamentally sound and the decision to initiate the share repurchase program illustrates the confidence we have in the long-term value of our company.”
Management is reviewing and considering a continuing program of actions to enable our company shares to become more accessible to a broader market of institutional investors.
According to company officials, the repurchase program may be suspended or discontinued at any time. Common stock acquired though the repurchase program will be held as treasury shares and may be used for general corporate purposes, including reissuances in connection with acquisitions, employee stock option exercises or other employee stock plans. Repurchases will be made under the program using Manhattan Scientifics’ own cash resources and will be in accordance with Rule 10b-18 under the Securities Exchange Act of 1934 and other applicable laws, rules and regulations. Maxim Group will act as agent for the company stock repurchase program.
Manhattan Scientifics makes nano medical technology.
“As part of our company’s long-term strategy to further develop its disruptive technologies, we have evaluated the recent price levels and we believe that our common stock represents an attractive investment opportunity for our company,” said Emmanuel Tsoupanarias, president and CEO of Manhattan Scientifics. “We believe that our company is fundamentally sound and the decision to initiate the share repurchase program illustrates the confidence we have in the long-term value of our company.”
Management is reviewing and considering a continuing program of actions to enable our company shares to become more accessible to a broader market of institutional investors.
According to company officials, the repurchase program may be suspended or discontinued at any time. Common stock acquired though the repurchase program will be held as treasury shares and may be used for general corporate purposes, including reissuances in connection with acquisitions, employee stock option exercises or other employee stock plans. Repurchases will be made under the program using Manhattan Scientifics’ own cash resources and will be in accordance with Rule 10b-18 under the Securities Exchange Act of 1934 and other applicable laws, rules and regulations. Maxim Group will act as agent for the company stock repurchase program.
Manhattan Scientifics makes nano medical technology.